Dec 15, 2018
Multiple Myeloma – An Introduction - Cancer.Net
Multiple Myeloma – An Introduction - Cancer.Net Multiple Myeloma – An Introduction Cancer.Net Learn more: Trusted, compassionate...
36
Dec 14, 2018
NCT03412565: Phase 2 - Subcutaneous Daratumumab in Combination With Standard MM Regimens - PLEIADES
PLEIADES study A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimen MMY2040...
622
Dec 14, 2018
NCT03757221: Phase 2 - IFM 2018-02 - Ixazomib -Daratumumab Without Dex in Elderly RRMM (IDARA)
NCT03757221: Phase 2 - Ixazomib -Daratumumab Without Dex (IDara) in Elderly RRMM (IDARA) IFM 2018-02 Phase 2 Study Elderly RRMM Ixazomib...
236
Dec 14, 2018
How can myeloma patients protect themselves from infections? International Myeloma Foundation
How can myeloma patients protect themselves from infections? International Myeloma Foundation How can myeloma patients protect themselves...
130
Dec 13, 2018
NCT03729804: Phase 3: KRd Versus VRd in Patients With Newly Diagnosed Multiple Myeloma (COBRA)
NCT03729804: Phase 3: Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in...
136
Dec 13, 2018
NCT03672318: Phase 1: Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma
NCT03672318: Phase 1: Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma The body has different ways of fighting...
126
Dec 13, 2018
NCT03435796: Phase 2/3: Long-Term Follow-up for Participants Treated With Gene-Modified T Cells
NCT03435796: Phase 2/3: Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells Long-Term Follow-up Protocol for...
53
Dec 13, 2018
NCI National Cancer Institute: Immunotherapy: How the Immune System Fights Cancer
NCI National Cancer Institute: Immunotherapy: How the Immune System Fights Cancer
123
Dec 13, 2018
NCT03606577: Phase 2-IFM 2018 - 04 - Quadruplet Induction & Consolidation + Tandem ASCT Hi Risk NDMM
IFM 2018-04 NCT03606577: Phase 2: An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell...
511
Dec 13, 2018
NCT03428373: Phase 2: Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma (RithMM)
NCT03428373: Phase 2: Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma (RithMM) NCT03428373: Phase 2: Rivaroxaban or...
57
Dec 13, 2018
NCT03752541: Allogeneic T-cells with Anti-BCMA CAR - BCMA-UCART in RRMM - Chinese study
NCT03752541: Efficacy and Safety Evaluation of BCMA-UCART AllogeneicT-cells with Anti-BCMA CAR Chimeric Antigen Receptor）in the Treatment...
59
Dec 12, 2018
FDA Approved for RRMM: Elotuzumab (Empliciti) with Pomalidomide and dexamethasone (Pd)
11/06/2018 : U.S. Food and Drug Administration Approves Empliciti® (elotuzumab) Plus Pomalidomide and Dexamethasone, a New Immunotherapy...
89
Dec 12, 2018
NCT03758417: Phase 2 - LCAR-B38M CAR-T Cells Against BCMA in Chinese relapsed Myeloma (CARTIFAN - 1)
The purpose of this study is to evaluate the efficacy and safety of LCAR-B38M chimeric antigen receptor T (CAR-T) cells. CHINESE STUDY A...
341
Dec 12, 2018
NCT03716856: Phase 1 - CAR-BCMA T in Patients With Refractory or Relapsed Multiple - Chinese study
NCT03716856: Phase 1 - Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma A single arm, open-label...
97
Dec 12, 2018
NCT03502577: Phase 1 - BCMA-Specific CAR T-Cells Combined With Gamma Secretase Inhibitor (JSMD194)
NCT03502577: Phase 1 - BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent...
104
Dec 12, 2018
NCT03773107: Phase 1/2: LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib RRMM
Multiple Myeloma Research Consortium NCT03773107: Phase 1/2: LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for...
142
Dec 11, 2018
IMF - International Myeloma Foundation: Patient Handbook
IMF - International Myeloma Foundation: Patient Handbook https://issuu.com/international-myeloma-foundation/docs/phb_en_2018?fr=sM2M2ZjQw...
98
Dec 10, 2018
IMF - International Myeloma Foundation: Understanding Freelite and Hevylite Tests
IMF - International Myeloma Foundation: Understanding Freelite and Hevylite Tests https://imf-d8-prod.s3.us-west-1.wasabisys.com/resource...
121
Dec 10, 2018
IMF - International Myeloma Foundation: Understanding Fatigue
IMF - International Myeloma Foundation: Understanding Fatigue https://imf-d8-prod.s3.us-west-1.wasabisys.com/resource/u-fatigue_0.pdf...
50